HIGHLIGHTS
- who: Jinsong Yang from the (UNIVERSITY) have published the Article: Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial, in the Journal: (JOURNAL) of January/26,/2021
- how: The authors calculated the sample size according to the design of a single-stage phase II clinical trial.
SUMMARY
Esophageal cancer is the seventh most common malignant tumor and the sixth leading cause of cancer death in the world. Surgical resection is the mainstay for locally advanced esophageal squamous cell . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.